Podimetrics

Executive Summary

Podimetrics is a digital health company dedicated to preventing severe complications in patients with complex diabetes, specifically diabetic foot ulcers (DFUs). Its flagship product, the SmartMat, is an FDA-cleared remote monitoring device that patients step on daily to detect early signs of foot inflammation, which often precedes ulcers. The device is paired with a high-touch clinical support program that alerts care teams to intervene proactively. By enabling early detection and intervention, Podimetrics aims to reduce hospitalizations, amputations, and overall healthcare costs. The company partners with payors, providers, and employers, demonstrating a scalable business model in value-based care. The diabetic foot ulcer market is sizable, with millions at risk and high associated costs. Podimetrics has secured commercial partnerships and shown positive clinical and economic outcomes in published studies. As healthcare shifts toward remote monitoring and preventive care, the company is well-positioned for growth. However, it operates in a competitive landscape with other digital health solutions. Key success factors include expanding payer coverage and demonstrating ROI to large customers. With a strong foundation and clear value proposition, Podimetrics has significant potential to scale and improve outcomes for diabetes patients.

Upcoming Catalysts (preview)

• Q1 2027Expansion of Medicare Coverage for SmartMat70% success
• Q3 2026Publication of New Clinical Outcomes Data85% success
• Q4 2026Series C Funding Round or Strategic Partnership60% success